# A Study of MLN0264 in Patients With Pancreatic Cancer

> **NCT02202785** · PHASE2 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** MLN0264

## Key facts

- **NCT ID:** NCT02202785
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-02
- **Primary completion:** 2016-01-15
- **Final completion:** 2016-01-15
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Business Decision, No Safety or Efficacy Concerns
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202785, "A Study of MLN0264 in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02202785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*